MX339184B - Panel multimarcador para hipertrofia ventricular izquierda. - Google Patents
Panel multimarcador para hipertrofia ventricular izquierda.Info
- Publication number
- MX339184B MX339184B MX2012002797A MX2012002797A MX339184B MX 339184 B MX339184 B MX 339184B MX 2012002797 A MX2012002797 A MX 2012002797A MX 2012002797 A MX2012002797 A MX 2012002797A MX 339184 B MX339184 B MX 339184B
- Authority
- MX
- Mexico
- Prior art keywords
- subject
- left ventricular
- markers
- ventricular hypertrophy
- amounts
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4712—Muscle proteins, e.g. myosin, actin, protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a un método de diagnosis o distinción, en un paciente que tiene hipertrofia ventricular izquierda, si el paciente tiene hipertrofia ventricular izquierda fisiológica o padece de hipertrofia ventricular izquierda patológica, el método comprende los pasos de a) determinar las cantidades al menos de un marcador seleccionado de los marcadores de necrosis, al menos un marcador seleccionado de los marcadores de la función cardiaca y al menos un marcador seleccionado de marcadores inflamatorios, al menos en una muestra del paciente, b) comparar las cantidades determinadas de esta forma de los marcadores que se determinan en el paso a) con las cantidades de referencia adecuadas, y c) diagnosticar si el paciente tiene hipertrofia ventricular izquierda fisiológica o si padece de hipertrofia ventricular izquierda patológica. La presente invención también se relaciona con un método que permite distinguir (diagnosticar), en un sujeto que padece de hipertrofia ventricular izquierda patológica, si el sujeto padece de cardiomiopatía no obstructiva hipertrófica, cardiomiopatía obstructiva hipertrófica, hipertrofia por sobrecarga de presión, que comprende los pasos de a) determinar las cantidades al menos de un marcador seleccionado de los marcadores de necrosis, y al menos un marcador seleccionado de los marcadores de la función cardiaca y al menos un marcador seleccionado de marcadores inflamatorios, al menos en una muestra del paciente, b) comparar las cantidades de referencia, y c) distinguir entre las diferentes formas de estas cardiomiopatías hipertróficas, dependiendo de los resultados del paso b). En modalidades preferidas de este método de la presente invención, se forma la relación de 2 marcadores. Opcionalmente, se mide otro marcador P1GF. Además, la presente invención se relaciona con un dispositivo y un kit adaptado para realizar el método de la presente invención. Uso de BNP (NT-proBNP), troponina T o I, GDF-15 y P1GF para distinguir en un paciente que tiene hipertrofia ventricular izquierda, si el paciente tiene hipertrofia ventricular izquierda fisiológica o padece de hipertrofia ventricular izquierda patológica.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09011888 | 2009-09-17 | ||
| PCT/EP2010/063637 WO2011033034A1 (en) | 2009-09-17 | 2010-09-16 | Multimarker panel for left ventricular hypertrophy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2012002797A MX2012002797A (es) | 2012-04-02 |
| MX339184B true MX339184B (es) | 2016-05-16 |
Family
ID=41508011
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012002797A MX339184B (es) | 2009-09-17 | 2010-09-16 | Panel multimarcador para hipertrofia ventricular izquierda. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20120164669A1 (es) |
| EP (1) | EP2478371B1 (es) |
| JP (1) | JP5717108B2 (es) |
| KR (1) | KR101522078B1 (es) |
| CN (1) | CN102498403B (es) |
| BR (1) | BR112012006105A2 (es) |
| CA (1) | CA2771171A1 (es) |
| ES (1) | ES2579953T3 (es) |
| HK (1) | HK1166370A1 (es) |
| MX (1) | MX339184B (es) |
| RU (1) | RU2548710C2 (es) |
| WO (1) | WO2011033034A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015171989A1 (en) * | 2014-05-08 | 2015-11-12 | University Of Maryland, Baltimore | Methods for assessing differential risk for developing heart failure |
| WO2016123163A2 (en) | 2015-01-27 | 2016-08-04 | Kardiatonos, Inc. | Biomarkers of vascular disease |
| JP6983223B2 (ja) * | 2016-04-18 | 2021-12-17 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 一般集団におけるｌｖｈへの進行因子の同定のための可溶性ｓｔ２ |
| EP3360570A1 (en) | 2017-02-13 | 2018-08-15 | Roche Diagnostics GmbH | Antibodies recognizing genetic variants |
| BR112019025387A2 (pt) * | 2017-05-30 | 2020-07-07 | Abbott Laboratories | métodos para auxiliar no diagnóstico e avaliação de uma lesão traumática cerebral branda em um indivíduo humano com o uso de troponina cardíaca i e biomarcadores precoces |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
| GB9211686D0 (en) | 1992-06-03 | 1992-07-15 | Medisinsk Innovation A S | Chemical compounds |
| AU8591198A (en) | 1997-07-31 | 1999-02-22 | Johns Hopkins University School Of Medicine, The | Growth differentiation factor-15 |
| JP2002543841A (ja) | 1999-05-17 | 2002-12-24 | バイオファーム ゲゼルシャフト ツア バイオテクノロジシェン エントヴィックルング ウント ツム フェルトリーブ フォン ファルマカ エムベーハー | ＴＧＦ−βスーパーファミリーの新規のメンバーであるＧＤＦ―１５の神経保護特性 |
| US6500630B2 (en) * | 2001-01-12 | 2002-12-31 | Mayo Foundation For Medical Education And Research | Marker for inflammatory conditions |
| US7632647B2 (en) | 2001-04-13 | 2009-12-15 | Biosite Incorporated | Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes |
| US7713705B2 (en) * | 2002-12-24 | 2010-05-11 | Biosite, Inc. | Markers for differential diagnosis and methods of use thereof |
| CA2414073A1 (en) | 2001-05-04 | 2002-11-14 | Gunars E. Valkirs | Diagnostic markers of acute coronary syndromes and methods of use thereof |
| CA2485722A1 (en) * | 2003-10-22 | 2005-04-22 | Paul Lehmann | Soluble transferrin receptor |
| WO2005113585A2 (en) | 2004-05-20 | 2005-12-01 | Acceleron Pharma Inc. | Modified tgf-beta superfamily polypeptides |
| EP1797199A2 (en) * | 2004-09-20 | 2007-06-20 | The Board of Trustees of Leland Stanford Junior University | Cardiac pressure overload associated genes |
| CA2580965C (en) * | 2004-09-22 | 2014-04-08 | Receptor Biologix, Inc. | Monoclonal antibodies to progastrin |
| ATE517341T1 (de) * | 2006-04-27 | 2011-08-15 | Critical Care Diagnostics Inc | Interleukin-33 (il-33) zur diagnose und vorhersage von herz-gefäss-erkrankungen |
| WO2008148193A1 (en) * | 2007-06-04 | 2008-12-11 | Centre For Addiction And Mental Health | Fhl1 mutations associated with novel x-linked muscular myopathies |
| RU2363000C2 (ru) * | 2007-08-03 | 2009-07-27 | Федеральное государственное учреждение Ростовский НИИ акушерства и педиатрии Федерального агентства по здравоохранению и социальному развитию | Способ диагностики степени нарушения функции сердечно-сосудистой системы у новорожденных из группы высокого перинатального риска |
| EP2037275A1 (en) * | 2007-09-11 | 2009-03-18 | F. Hoffmann-La Roche AG | Differentiation of different causes of right heart failure |
| JP2011501112A (ja) * | 2007-10-10 | 2011-01-06 | エフ．ホフマン−ラ ロシュ アーゲー | 心筋梗塞のモニタリング及びその治療のための手段及び方法 |
| EP2090891A1 (en) * | 2008-02-13 | 2009-08-19 | F.Hoffmann-La Roche Ag | Means and methods for determining the atherosclerotic load using the biomarker PLGF |
| AU2009313561A1 (en) * | 2008-11-06 | 2011-06-30 | Musc Foundation For Research Development | Detecting and monitoring left ventricular hypertrophy and congestive heart failure by profiling biomarkers |
-
2010
- 2010-09-16 CN CN201080041316.5A patent/CN102498403B/zh active Active
- 2010-09-16 KR KR1020127006944A patent/KR101522078B1/ko active IP Right Grant
- 2010-09-16 ES ES10752842.4T patent/ES2579953T3/es active Active
- 2010-09-16 JP JP2012529274A patent/JP5717108B2/ja active Active
- 2010-09-16 RU RU2012115125/15A patent/RU2548710C2/ru active
- 2010-09-16 EP EP10752842.4A patent/EP2478371B1/en active Active
- 2010-09-16 BR BR112012006105A patent/BR112012006105A2/pt not_active IP Right Cessation
- 2010-09-16 WO PCT/EP2010/063637 patent/WO2011033034A1/en active Application Filing
- 2010-09-16 MX MX2012002797A patent/MX339184B/es active IP Right Grant
- 2010-09-16 CA CA2771171A patent/CA2771171A1/en not_active Abandoned
-
2012
- 2012-03-09 US US13/416,579 patent/US20120164669A1/en not_active Abandoned
- 2012-07-18 HK HK12107024.1A patent/HK1166370A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CN102498403B (zh) | 2015-09-16 |
| JP2013505437A (ja) | 2013-02-14 |
| AU2010297279A1 (en) | 2012-03-15 |
| BR112012006105A2 (pt) | 2016-06-07 |
| KR101522078B1 (ko) | 2015-05-20 |
| MX2012002797A (es) | 2012-04-02 |
| JP5717108B2 (ja) | 2015-05-13 |
| KR20120092571A (ko) | 2012-08-21 |
| RU2012115125A (ru) | 2013-10-27 |
| ES2579953T8 (es) | 2016-08-26 |
| CA2771171A1 (en) | 2011-03-24 |
| CN102498403A (zh) | 2012-06-13 |
| WO2011033034A1 (en) | 2011-03-24 |
| ES2579953T3 (es) | 2016-08-17 |
| HK1166370A1 (en) | 2012-10-26 |
| US20120164669A1 (en) | 2012-06-28 |
| EP2478371A1 (en) | 2012-07-25 |
| RU2548710C2 (ru) | 2015-04-20 |
| EP2478371B1 (en) | 2016-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX339184B (es) | Panel multimarcador para hipertrofia ventricular izquierda. | |
| ATE373827T1 (de) | Kombination von markern für diabetes typ 1 und 2 | |
| EP2770328A3 (en) | Method to diagnose pancreatic cancer | |
| ATE469353T1 (de) | Verwendung von nt-proanp und nt-probnp zur diagnose von herzerkrankungen | |
| WO2009047283A3 (en) | Means and methods for monitoring myocardial infarction and its treatment | |
| EP2434283A3 (en) | Diagnosis of preeclampsia | |
| EP2674435A3 (en) | Biomarkers useful for diagnosing prostate cancer, and methods thereof | |
| WO2009137015A3 (en) | Biomarkers of ionizing radiation | |
| ATE412910T1 (de) | Verwendung von herzhormonen zur diagnose des kardiovaskuläre risikos als folge einer verabreichung von entzündungshemmern | |
| BR0316231A (pt) | Métodos para determinar o estado de sepsia para prognosticar o começo de sepsia e para diagnosticar a sìndrome de resposta inflamatória sistêmica em um indivìduo e para isolar um biomarcador, perfil biomarcador r kit | |
| ATE438860T1 (de) | P1gf und flt-1 als prognostische parameter bei kardiovaskulären erkrankungen | |
| WO2005071407A3 (en) | Methods of diagnosing acute coronary syndrome by measuring urotensin ii | |
| DE60233301D1 (de) | Diagnostische marker für akute herzerkrankungen und verfahren des gebrauchs | |
| DE602005001299D1 (de) | Kombinationen von Markern zum Nachweis von typ 1 und 2 Diabetes | |
| WO2007103116A3 (en) | Methods and systems for evaluating health risk factors by measurement of dna damage and dna repair | |
| WO2009152607A8 (en) | Methods and kits for diagnosing neurodegenerative disease | |
| CY1115080T1 (el) | Μεθοδοι και kit για να διαγνωσκεται ανεπαρκεια αυξητικης ορμονης | |
| WO2005085292A3 (fr) | Procede de detection de la forme libre activable du psa et son utilisation pour le diagnostic des pathologies benignes de la prostate et de l'adenocarcinome de la prostate | |
| RU2008103988A (ru) | Способ диагностики рассеяного склероза | |
| DE60025347D1 (de) | Methoden zur vohersage eines schwangerschaftsergebnisses bei einer testperson mit hilfe eines hcg-tests | |
| ATE537454T1 (de) | Verfahren zum beurteilen von herzinsuffizienz bei patienten mit vorhofflimmern mittels gdf-15 | |
| WO2005093103A3 (en) | Development and use of fluorescent probes of unbound analytes | |
| RU2015129496A (ru) | Острая почечная недостаточность | |
| EP3178846A3 (en) | Novel phosphorylation of cardiac troponin i as a monitor for cardiac injury | |
| WO2005023291A3 (en) | Use of glp1-agonists in the treatment of patients with type i diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |